論文・出版
Outcomes of Trastuzumab Therapy in HER2-Positive Early Breast Cancer Patients: Extended Follow-up of JBCRG-Cohort Study 01
Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, Naohito Yamamoto, Reiki Nishimura, Shoichiro Ohtani, Nobuaki Sato, Masato Takahashi, Takako Kamio, Kosuke Yamazaki, Tsuyoshi Saito, Makoto Kato, Tecchuu Lee, Katsumasa Kuroi, Toshimi Takano, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi, JBCRG-C01 Collaborative Group Collaborators,
Breast Cancer. 2020 Jul; 27(4): 631-641. Epub 2020 Feb 14.
https://doi.org/10.1007/s12282-020-01057-4
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority (phase III) trial in Japan (JBCRG-M06/EMERALD)
Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno
Trials. 2020 May; 21(1): 391.
https://doi.org/10.1186/s13063-020-04341-y
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer (JBCRG-09)
Hiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka-Mizuno, and Masakazu Toi
Breast Cancer Research and Treatment. 2020; 180: 715–724.
https://doi.org/10.1007/s10549-020-05590-w
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer (JBCRG-20 study)
Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi
Breast Cancer Research and Treatment. 2020; 180: 135–146.
https://doi.org/10.1007/s10549-020-05524-6
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
Takayuki Ueno, Norikazu Masuda, Nobuaki Sato, Shoichiro Ohtani, Jun Yamamura, Nobuki Matsunami, Masahiro Kashiwaba, Toshimi Takano, Masato Takahashi, Koji Kaneko, Shinji Ohno, Satoshi Morita, and Masakazu Toi
Japanese Journal of Clinical Oncology, 2020, 50(1)3–11
https://doi.org/10.1093/jjco/hyz119
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
Breast Cancer. 2020; 27: 389–398.
https://doi.org/10.1007/s12282-019-01029-3
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (JBCRG-12/15)
Hiroshi Ishiguro, Shinji Ohno, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi
Breast Cancer. 2019 Sep; 26(5): 535-543. Epub 2019 Feb 7.
https://doi.org/10.1007/s12282-019-00952-9
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (JBCRG-11TC)
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Cancer Medicine. 2019 Sep; 8(12): 5468-5481. Epub 2019 Jul 30.
https://doi.org/10.1002/cam4.2423
Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Shigehira Saji, Shigeru Imoto, Hironobu Sasano, Masakazu Toi
International Journal of Molecular Science. 2019; 20(4): 984.
https://doi.org/10.3390/ijms20040984
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03
Yasuaki Sagara, Masahiro Takada, Yasuyo Ohi, Shoichiro Ohtani, Sasagu Kurozumi, Kenichi Inoue, Yoshimasa Kosaka, Masaya Hattori, Toshinari Yamashita, Shintaro Takao, Nobuaki Sato, Hiroji Iwata, Masafumi Kurosumi, Masakazu Toi
Breast Cancer Research and Treatment. 2018 Oct; 171(3): 675-683. Epub 2018 Jul 3.
https://doi.org/10.1007/s10549-018-4873-0